NASDAQ:LVTX LAVA Therapeutics Q4 2024 Earnings Report $1.36 +0.01 (+0.73%) Closing price 07/11/2025 03:56 PM EasternExtended Trading$1.36 0.00 (-0.29%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast LAVA Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.32Beat/MissBeat by +$0.18One Year Ago EPSN/ALAVA Therapeutics Revenue ResultsActual Revenue$2.50 millionExpected Revenue$2.40 millionBeat/MissBeat by +$104.00 thousandYoY Revenue GrowthN/ALAVA Therapeutics Announcement DetailsQuarterQ4 2024Date3/28/2025TimeBefore Market OpensConference Call DateFriday, March 28, 2025Conference Call Time7:30AM ETUpcoming EarningsLAVA Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 19, 2025, with a conference call scheduled on Wednesday, August 20, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) LAVA Therapeutics Earnings HeadlinesLAVA Therapeutics Shareholders Approve Key Proposals in MeetingJune 13, 2025 | tipranks.comHere's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn SituationMay 16, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history. | Paradigm Press (Ad)LAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 15, 2025 | finanznachrichten.deLAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 14, 2025 | globenewswire.comLAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock NewsApril 16, 2025 | gurufocus.comSee More LAVA Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LAVA Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LAVA Therapeutics and other key companies, straight to your email. Email Address About LAVA TherapeuticsLAVA Therapeutics (NASDAQ:LVTX), Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation cancer immunotherapies. The company’s proprietary platform leverages the unique biology of gamma delta (γδ) T cells—immune cells that combine innate and adaptive functions—to create bispecific and multispecific antibodies designed to recruit and activate γδ T cells against a broad range of solid tumors and hematological malignancies. At the core of LAVA’s pipeline is its Gammabody® platform, which engineers antibodies to precisely engage γδ T cell receptors in conjunction with tumor-associated antigens. Lead candidates include LAVA-051, a first-in-class bispecific targeting Vγ9Vδ2 T cells and CD1d for the treatment of hematological cancers, and LAVA-1207, which recruits Vγ9Vδ2 T cells to prostate-specific membrane antigen (PSMA) in prostate cancer. Additional preclinical programs aim to expand the technology to other solid tumor indications and novel tumor-specific targets. Founded in 2016 and headquartered in Amsterdam with a research and clinical development presence in Boston, Massachusetts, LAVA has built a multidisciplinary team comprising immunologists, antibody engineers and clinical development experts. The company completed its initial public offering on the Nasdaq in 2021. Under the leadership of Chief Executive Officer J.P. Castaigne and Chief Scientific Officer Andreas Hofmann, LAVA continues to advance its portfolio through regulatory filings and early-stage clinical trials across Europe and North America.Written by Jeffrey Neal JohnsonView LAVA Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
